IGHE and anaphylaxis: In the Phase I trial, we showed that prior to the administration of MOv18 IgE, the BAT predicted the anaphylaxis experienced by one patient and can now be used to exclude patients in future trials that have the potential to develop type I hypersensitivity [18].